Figure 5: Anti-tumour effects of an anti-miR-199a-5p oligonucleotide (miR-199a-5p AMO) in vivo.
From: MicroRNA-199a-5p promotes tumour growth by dual-targeting PIAS3 and p27 in human osteosarcoma
(A) The relative expression of miR-199a-5p in MNNG/HOS cells 24 hours after transfection with the miR-199a-5p AMO or scramble DNA. (B) The protein level of PIAS3 and p27 in MNNG/HOS cells 24 hours after transfected with miR-199a-5p AMO or scramble DNA. (C) The volumes of the xenograft tumours in nude mice determined at 9, 12, 15, 18, 21, 24, 27, 30, and 33 days tumours transplantation, followed by intratumoral treatment with miR-199a-5p AMO on day 9 after tumours transplantation. (D) The weights of the xenograft tumours in nude mice measured at 33 days after tumours transplantation, followed by intratumoral treatment with miR-199a-5p AMO on day 9 after tumours transplantation. (E) A representative photograph of tumour-bearing mice 33 days after tumours transplantation and intratumoral injection with miR-199a-5p AMO. (F) A representative photograph of tumours excised from tumour-bearing mice, 33 days after tumours transplantation and intratumoral injection with miR-199a-5p AMO. (G) QRT-PCR analysis of miR-199a-5p and (I) QRT-PCR analysis of PCNA and KI-67 in the xenograft tumours in nude mice 33 days after tumours transplantation and intratumoral injection with miR-199a-5p AMO. The data are expressed as the means ± SEM, **P < 0.01. (H) Western blot analysis of PIAS3 and p27 in the xenograft tumours in nude mice 33 days after tumours transplantation and intratumoral injection with miR-199a-5p AMO.
